Posted on 469
ResearchAndMarkets.com’s offering.
The “Adult-onset Still’s Disease Market Insights, Epidemiology, and Market Forecast – 2030” report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the market trends of adult-onset Still’s disease in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The adult-onset Still’s disease (AOSD) market report provides analysis regarding current treatment practices, emerging drug-like CERC-007 (Cerecor) and potential therapies, market share of the individual therapies, historical, current, and forecasted adult-onset Still’s disease market size from 2017 to 2030, segmented by seven major markets.
The report also covers current adult-onset Still’s disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assess t
Adult-onset Still s Disease Market Insights, Epidemiology, and Market Forecast to 2030 - ResearchAndMarkets com - Press Release
digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.
Adult-onset Still s Disease Epidemiology Forecast to 2030 - ResearchAndMarkets com - Press Release
digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.
ResearchAndMarkets.com’s offering.
“ANAKINRA- Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Adult-onset Still’s Disease in 7 Major Markets. A detailed picture of the ANAKINRA in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.
The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Tocilizumab Emerging Insight and Market Forecast Report 2020-2030 - ResearchAndMarkets.com
December 16, 2020 GMT
DUBLIN (BUSINESS WIRE) Dec 16, 2020
“TOCILIZUMAB- Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Adult-onset Still’s Disease in 7 Major Markets.
ADVERTISEMENT
Tocilizumab (INN, trade name Actemra), also known as atlizumab, is an immunosuppressive drug. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases.